Stock OMIC SINGULAR GENOMICS SYSTEMS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Market Closed - Nasdaq
Other stock markets
 01:30:00 01/05/2024 am IST 		5-day change 1st Jan Change
0.401 USD +0.88% Intraday chart for Singular Genomics Systems, Inc. -3.23% -12.85%
20/03 UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating MT
18/03 Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024

Summary

  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SINGULAR GENOMICS SYSTEMS, INC. Stock Singular Genomics Systems, Inc.
-12.85% 29.71M
D+
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.19B
B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.24B
B-
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 24.63B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.2B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.01B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.76B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 10.4B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. OMIC Stock
  4. Ratings Singular Genomics Systems, Inc.